NASDAQ · LGVN
Healthcare · Biotechnology
$6.58
Up+$0.06 (+0.91%)
Updated Sep 10, 2026, 11:26 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
LGVN closed at $6.58 after 20 trading sessions, up 780.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $6.58 | $6.75 | $6.51 | $6.58 | 29.57K |
| Sep 8, 2026 | $6.78 | $6.90 | $6.56 | $6.65 | 50.15K |
| Sep 4, 2026 | $6.54 | $6.88 | $6.53 | $6.81 | 41.24K |
| Sep 3, 2026 | $6.82 | $7.0399 | $6.55 | $6.58 | 43.96K |
| Sep 2, 2026 | $6.67 | $6.9482 | $6.6503 | $6.78 | 36.04K |
| Sep 1, 2026 | $6.86 | $7.0453 | $6.61 | $6.75 | 32.52K |
| Aug 31, 2026 | $6.75 | $7.299 | $6.51 | $6.90 | 106.93K |
| Aug 28, 2026 | $6.80 | $7.25 | $6.5501 | $6.72 | 79.78K |
| Aug 27, 2026 | $7.06 | $7.28 | $6.59 | $6.80 | 130.24K |
| Aug 26, 2026 | $6.86 | $7.40 | $6.76 | $7.033 | 66.6K |
| Aug 25, 2026 | $7.30 | $7.345 | $6.50 | $6.80 | 159.21K |
| Aug 24, 2026 | $8.50 | $8.70 | $8.049 | $8.378 | 93.96K |
| Aug 21, 2026 | $8.60 | $8.70 | $8.231 | $8.449 | 77.04K |
| Aug 20, 2026 | $0.84 | $0.89 | $0.8176 | $0.8282 | 618.69K |
| Aug 19, 2026 | $0.8115 | $0.88 | $0.80 | $0.8223 | 1.11M |
| Aug 18, 2026 | $0.80 | $0.83 | $0.7663 | $0.7872 | 504.92K |
| Aug 17, 2026 | $0.75 | $0.84 | $0.74 | $0.82 | 1.23M |
| Aug 14, 2026 | $0.7021 | $0.7549 | $0.7002 | $0.7399 | 298.77K |
| Aug 13, 2026 | $0.6701 | $0.7299 | $0.67 | $0.6976 | 534.67K |
| Aug 12, 2026 | $0.7149 | $0.79 | $0.7045 | $0.7469 | 922.86K |
The latest Smart Investors Daily articles mentioning LGVN.
LGVN research
Company profile and research snapshot.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 11, 2026 | Maxim Group | Hold | — |
| May 4, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | Roth Capital | Buy | — |
| Mar 21, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 3, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 25, 2026
U.S. stock futures advanced on Tuesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Monday's mixed close.
Benzinga · Aug 25, 2026
US stock futures mixed as investors focus on earnings from Dick's Sporting Goods, Trade Desk, Intuit, Longeveron, and Zoom Communications.
Benzinga · Aug 24, 2026
Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will
Benzinga · Aug 19, 2026
Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LGVN.
